FdaApplication
NDA 021227
Identifiers
- fda_app_no: NDA021227
Properties
| Property | Value |
|---|---|
| applicant_name | MERCK AND CO INC |
| application_type | NDA |
| approval_date | 2001-01-26 |
Revenue by product
CANCIDAS
| Period | Revenue |
|---|---|
| Q4 2022 | $36.0M |
| Q3 2022 | $43.0M |
| Q2 2022 | $42.0M |
| Q1 2022 | $53.0M |
| Q4 2021 | $44.0M |
| Q3 2021 | $56.0M |
| Q2 2021 | $54.0M |
| Q1 2021 | $57.0M |
| Q4 2020 | $65.0M |
| Q3 2020 | $50.0M |
| Q2 2020 | $43.0M |
| Q1 2020 | $55.0M |
| Q4 2019 | $58.0M |
| Q3 2019 | $62.0M |
| Q2 2019 | $67.0M |
| Q1 2019 | $61.0M |
| Q4 2018 | $69.0M |
| Q3 2018 | $79.0M |
| Q2 2018 | $87.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| CANCIDAS | CASPOFUNGIN ACETATE | 50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | POWDER;INTRAVENOUS |
| CANCIDAS | CASPOFUNGIN ACETATE | 70MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | POWDER;INTRAVENOUS |
2 products